Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

WHO advise against international control of ketamine
Ketamine
Ketamine is often the only anaesthetic agent available in most developing countries and is also used for pain management.

Committee concludes medical benefits far outweigh potential harm 

Ketamine should not be placed under international control because it does not pose a threat to public health, the World Health Organisation has announced.

It is the fourth time since 2006 that the organisation has made the recommendation and follows a review of the latest evidence by the WHO Expert Committee on Drug Dependence.

The committee concluded that ketamine abuse does not pose a global public health threat, while controlling it could limit access to the only anaesthetic and pain killer available in large areas of the developing world.

“The medical benefits of ketamine far outweigh potential harm from recreational use,” said Marie-Paule Kieny, assistant-director general for health systems and innovation at WHO.

“Controlling ketamine internationally could limit access to essential and emergency surgery, which would constitute a public health crisis in countries where no affordable alternatives exist.”

Used in surgical and diagnostic procedures, ketamine is often the only anaesthetic agent available in most developing countries and is also used for pain management.

Ketamine has a great safety record, but recently it has also been used recreationally, prompting moves to control the substance under international law.

On each of these occasions - in 2006, 2012, 2014 and this year – the WHO Committee has recommended against scheduling. This and other recommendations of the Expert Committee will be conveyed to the Commission on Narcotic Drugs for its final decisions in March 2016.

“We have found that placing substances under international control can often limit access to them for medical purposes,” said Kees De Joncheere, WHO director for essential medicines and health products.

“Morphine is a case in point: even though it is inexpensive and one of the best substances available for pain management, in most countries availability and use are limited due to excessive regulation.”

Image (C) Psychonaught

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.